Synlogic Granted U.S. Patent #11723932: Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
Portfolio Pulse from Charles Gross
Synlogic has been granted U.S. Patent #11723932, which pertains to microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells. This could potentially lead to advancements in cancer treatment.
August 15, 2023 | 3:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The granting of the patent to Synlogic could potentially lead to advancements in cancer treatment, which may positively impact the company's stock in the short term.
The granting of a patent is a positive development for a biotech company like Synlogic, as it provides them with exclusive rights to their invention. This could potentially lead to advancements in cancer treatment, which could increase the company's revenues and positively impact the stock price.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100